LOADING
At insitro, we're revolutionizing drug development. We fuse cutting-edge machine learning with large-scale biology and modality-independent drug discovery to tackle major bottlenecks in the pipeline. We've built a leading platform and a team of incredibly talented scientists driven to make a real difference.
We're looking for an experienced and dynamic leader to be our VP, Bioassays, Cell Models, and Genomic Screening. This is a pivotal role in shaping and executing insitro's CellML platform. You'll lead the charge in developing and integrating cell models that truly mimic human biology, crafting innovative bioassays, and overseeing our cell-based arrayed and pooled optical screening platforms to accelerate both target and drug discovery.
You'll be a central figure, collaborating closely with senior management and teams across therapeutic areas, functional genomics, drug discovery, automation, and machine learning. Your mission: ensure our models, assays, and screening efforts precisely meet the demands of our discovery pipeline and platform execution.
This is your chance to join a well-funded AI biotech that's already building a robust pipeline of therapeutic candidates. We're still laying the foundation, which means immense opportunities for you to make a significant impact. You'll work alongside brilliant minds in data science, machine learning, biology, automation, and drug development, applying your expertise to shape insitro's culture, strategic direction, and the success of our discovery platforms.
You'll report to the Chief Technical Operations Officer at our South San Francisco office, with at least three days a week onsite. Some travel for conferences, collaborations, and regulatory interactions may also be required.
Join us and help us make a profound difference for patients!
Our target starting salary for successful US-based applicants for this role is $290,000 - $326,000. To determine starting pay, we consider multiple job-related factors including a candidate's skills, education and experience, market demand, business needs, and internal parity. We may also adjust this range in the future based on market data.
This role is eligible for participation in our Annual Performance Bonus Plan (based on company targets by role level and annual company performance) and our Equity Incentive Plan, subject to the terms of those plans and associated policies.
In addition, insitro also provides our employees:
insitro is an equal opportunity employer. All applicants will be considered for employment without attention to race, color, religion, sex, sexual orientation, gender identity, national origin, veteran or disability status.
We believe diversity, equity, and inclusion need to be at the foundation of our culture. We work hard to bring together diverse teams–grounded in a wide range of expertise and life experiences–and work even harder to ensure those teams thrive in inclusive, growth-oriented environments supported by equitable company and team practices. All candidates can expect equitable treatment, respect, and fairness throughout the interview process.
Please be aware of recruitment scams: we never request payments, all recruitment communications are from @insitro.com, and if in doubt, contact us at info@insitro.com throughout the interview process.
#LI-Hybrid
insitro is a drug discovery and development company using machine learning (ML) and data at scale to decode biology for transformative medicines. At the core of insitro's approach is the convergence of in-house generated multi-modal cellular data and high-content phenotypic human cohort data. We rely on these data to develop ML-driven, predictive disease models that uncover underlying biologic state and elucidate critical drivers of disease. These powerful models rely on extensive biological and computational infrastructure and allow insitro to advance novel targets and patient biomarkers, design therapeutics and inform clinical strategy. insitro is advancing a wholly owned and partnered pipeline of insights and therapeutics in neuroscience and metabolism. Since launching in 2018, insitro has raised over $700 million from top tech, biotech and crossover investors, and from collaborations with pharmaceutical partners. For more information on insitro, please visit www.insitro.com.